This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montanari, M. P.
Right arrow Articles by Varaldo, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montanari, M. P.
Right arrow Articles by Varaldo, P. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3616-3622, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3616-3622.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Antibacterial Activities of AF 3013, the Active Metabolite of Prulifloxacin, against Nosocomial and Community Italian Isolates

Maria Pia Montanari, Marina Mingoia, and Pietro Emanuele Varaldo*

Institute of Microbiology, University of Ancona Medical School, 60131 Ancona, Italy

Received 16 April 2001/Returned for modification 30 July 2001/Accepted 4 September 2001

AF 3013, the active metabolite of prulifloxacin, was tested to determine its inhibitory and bactericidal activities against 396 nosocomial and 258 community Italian isolates. Compared with that of ciprofloxacin, its activity (assessed in MIC and minimal bactericidal concentration tests) was generally similar or greater against gram-positive bacteria and greater against gram-negative bacteria. In time-kill assays using selected isolates, its bactericidal activity was comparable to that of ciprofloxacin.

* Corresponding author. Mailing address: Institute of Microbiology, University of Ancona Medical School, Via Ranieri, Monte d'Ago, 60131 Ancona, Italy. Phone: 39 071 2204694. Fax: 39 071 2204693. E-mail: pe.varaldo{at}popcsi.unian.it.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3616-3622, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3616-3622.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fritsche, T. R., Biedenbach, D. J., Jones, R. N. (2009). Antimicrobial Activity of Prulifloxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler's Diarrhea. Antimicrob. Agents Chemother. 53: 1221-1224 [Abstract] [Full Text]  
  • Pasqua, F., Biscione, G., Crigna, G., Cazzola, M. (2008). Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers. Ther Adv Respir Dis 2: 209-214 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»